ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate...